Therefore, the inhibitory effect of HER2-nanobody on the proliferation and pro-apoptosis in HER2-positive breast cancer cells might be achieved by inhibiting the phosphorylation of ERK and AKT. This evidence concerns the gene AKT1 and breast carcinoma.